EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

doi 10.21608/resoncol.2014.461

Full Text

Abstract

Available in

Date

October 1, 2014

Authors

Ehab Ibrahim

Publisher

Egypts Presidential Specialized Council for Education and Scientific Research

Related search

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Journal of Thoracic Oncology

English

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

English

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Journal of Thoracic Oncology

English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

Targeting Alveolar Macrophages Shows Better Treatment Response Than Deletion of Interstitial Macrophages in EGFR Mutant Lung Adenocarcinoma

Immunity, inflammation and disease

Allergy

Immunology

2020

English

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

English

Amanote Research

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

Full Text

Abstract

Date

Authors

Publisher

Related search

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

Targeting Alveolar Macrophages Shows Better Treatment Response Than Deletion of Interstitial Macrophages in EGFR Mutant Lung Adenocarcinoma

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma